Company intelligence
GG Ventures
Backing AI-native founders rearchitecting systems at the intersection of Health, Sports, and Longevity
About GG Ventures
GG Ventures - Investing in The Female Performance Stack A $1T+ opportunity unfolding at the intersection of health, sports, and longevity - reimagined through a female lens. We’re not indexing the category, we’re defining it. GG Ventures is Europe’s first and only investment platform focused on female performance. Investing since 2021, we’re now raising a $100M institutional Fund II to back AI-native, science-led companies reengineering the female health stack from the ground up. We invest at the inflection point—between Seed and Series A, where founder–market fit, data moats, and machine learning DNA converge to create exponential, compounding value. We partner with founders of any gender building from first principles, with AI as the engine. We back AI-native companies with proprietary data flywheels, predictive architectures that improve autonomously with every use, regulatory-grade infrastructure aligned with payers and globally compliant from day one, and defensible, scalable IP. Where we play: 1. Sports, Strength & Wellness 2. Next Gen Reproductivity 3. Longevity & Chronic Diseases 4. 7 Female Cancers 5. Mental Health / HealthTech Products & Services We leverage elite women’s sport as a high-velocity distribution engine—fueling access, adoption, and authenticity at scale. This isn’t niche. This is foundational to global health, economic resilience, and generational continuity. We’re not just backing the future of female performance, we’re engineering it.
Verified activity
Signals from GG Ventures
6 published signals
Presence & Recognition
GG Ventures spoke at the Women's Sport Summit, Europe 2026, on the 6th October at the Emirates stadium, alongside Katharine Curran of Monarch Collective, Assia Grazioli-Venier of Muse Capital, and Samir Beg Ceric of Ceric & Co.
Reported by Priya Oberoi
Products & Services
GG Ventures partnered with Twentyeight Health to feed cycle and recovery data from a wearable to a clinician who can prescribe or refer a member for a long-acting contraceptive to be fitted.
Reported by GG Ventures
Products & Services
GG Ventures announced hormonal symptom insights and predictions, a model based on individual physiological data and historical patterns, alongside Menopause Insights and its Menopause Impact Scale.
Reported by GG Ventures
Products & Services
GG Ventures shipped ŌURA period prediction in late 2022 and Cycle Insights in 2023, with WHOOP reporting 111% YoY growth in women's membership this August.
Reported by GG Ventures
Products & Services
GG Ventures partnered with WHOOP in September 2025 to integrate clinician-reviewed lab testing with wearable data, and announced 11 female-specific biomarkers including AMH, progesterone, prolactin, and thyroid peroxidase antibodies in March 2026.
Reported by GG Ventures
Presence & Recognition
GG Ventures participated in a discussion at Google London hosted by TechThrive Ventures on where capital is flowing across health, longevity, and the emerging care economy.
Reported by Priya Oberoi